References
- Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103(7), 1330–1335 (2005).
- Akaishi J, Sugino K, Kitagawa W et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 21(11), 1183–1189 (2011).
- Cooper DS, Doherty GM, Haugen BR et al.; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167–1214 (2009).
- American Joint Cancer Committee. In: AJCC Cancer Staging Manual (7th Edition). Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). Springer, IL, USA (2010).
- Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J. Surg. 36(6), 1247–1254 (2012).
- Marlow LA, D’Innocenzi J, Zhang Y et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J. Clin. Endocrinol. Metab. 95(12), 5338–5347 (2010).
- Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16(1), 17–44 (2009).
- Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer. Mol. Aspects Med. 31(2), 215–226 (2010).
- Wein RO, Weber RS. Anaplastic thyroid carcinoma: palliation or treatment? Curr. Opin. Otolaryngol. Head Neck Surg. 19(2), 113–118 (2011).
- Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol. 33(4), 341–357 (2008).
- Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 92(8), 2902–2909 (2007).
- Nehs MA, Nucera C, Nagarkatti SS et al. Late intervention with anti-BRAF (V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 153(2), 985–994 (2012).
- Catalano MG, Fortunati N, Pugliese M et al. Histone deacetylase inhibition modulates e-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 97(7), e1150–e1159 (2012).
- Marlow LA, Reynolds LA, Cleland AS et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 69(4), 1536–1544 (2009).
- D’Agostino M, Voce P, Celano M et al. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22(2), 138–144 (2012).
- Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib – a case report. Anticancer Res. 32(5), 1743–1746 (2012).
- Derbel O, Limem S, Ségura-Ferlay C et al. Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 11, 469 (2011).